Product Portfolio

Product Portfolio

Certain target classes (Ion Channels, G-protein Coupled Receptor, Protein-Protein Interactions) offer opportunities where small molecules and standard monoclonal antibodies have failed. Delivery of biologics to certain tissues like the central nervous system and neuromuscular junction also remains a major obstacle. Ossianix is leveraging the unique structural features of the VNAR to address these areas of unmet medical need and is developing a pipeline of innovative products for the treatment of Neurological, Neuromuscular and Autoimmune Disease that are proceeding to IND.

  • OSX100 is a VNAR product that targets and antagonizes the B-cell activator, BAFF. The product is a potent and selective inhibitor that protrudes into the receptor-binding cavity on BAFF. OXS100 has shown preclinical efficacy by depleting selective B-cell populations and is being targeted for the treatment of Myositis but has utility in a broad range of inflammatory conditions.
  • OSX110 is the BAFF antagonist OSX100 targeted to CNS disease by fusion to a transferrin receptor binding VNAR. OSS110 is being tested in animal models of Neuroinflammation with a focus on secondary progressive multiple sclerosis where pathogenesis involves the formation of ectopic B-cell follicles. OSS110 uniquely targets this mechanism, which might also be relevant to cerebral lupus.
  • OSX200 is a myostatin antagonist for the treatment of neuromuscular diseases. Myostatin functions as a negative regulator of muscle growth and multiple approaches have confirmed that its neutralization leads to an increase in muscle mass. OSX220 is a potent myostatin antagonist that dramatically increases muscle mass in preclincal models and is being developed for Orphan diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
  • OSX300 and backup molecules are a series of VNARs that bind with high affinity to the P2X3 receptor. P2X3 receptors respond to the release of ATP from injured tissues and VNAR antagonists are being developed for the management of chronic pain. This program is partnered with Lundbeck A/S.
  • OSX400 and backups are a series of VNARs that bind to the botulinum toxin light chain protease. This project is sponsored by the US Army Medical Research Institute of Chemical Defense as part of a multi-centre program focused on the development of therapeutics for the treatment of the lethal neurotoxin produced by the bacterium Clostridium botulinum.
  • OSX500, OSX600 and OSX700 are drug discovery programs targeting different mechanisms associated with neurodegeneration, pain and obesity and are targeting previously intractable targets such as ion channels and G protein-coupled receptors.